Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Michael J. Morris, MD, member of the medical oncology and genitourinary oncology services at Memorial Sloan Kettering Cancer Center, was a discussant on the ECOG-led phase III randomized CHAARTED trial that studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Dr. Morris talks about side effects seen during the trial, what accounted for the increase in the time to development of castration resistance seen, as well as what he thinks the effect will be if results of the FIRSTANA trial show cabazitaxel to be superior to docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.